Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Gov won't say if Paxlovid is accessible

Officials won't say how many people have received antiviral pills, or if they're being equitably distributed

Salon

Only 7% of 5-11s in England have had Covid jab as parents hesitate

Six weeks after start of vaccine rollout, fraction of young children have had first dose as parents question usefulness

The Guardian - UK

We looked into the lobby group taking on rugby star turned would-be senator David Pocock. Here's what we found

Conservative lobby group Advance Australia has independent ACT Senate candidate David Pocock in its sights, with Facebook advertising data revealing that the group's offensive against the former rugby star is disproportionate to its campaigning against any other candidate.

ABC News

From analysis to the latest developments in health,
read the most diverse news in one place.

Price Of Pfizer's Paxlovid Generic Version Capped At $25 Or Less For Low-Income Countries

Several generic drugmakers will produce cheaper versions of Pfizer Inc's (NYSE:PFE) COVID-19 antiviral treatment Paxlovid at $25/course or less for low- and middle-income countries, Reuters reported citing the Clinton Health Access Initiative (CHAI). CHAI said it could not disclose the manufacturers' names who have agreed to the price ceiling because they are still in…

Benzinga

Moderna Concludes FDA Submission For Its COVID-19 Shot In Adolescents, Kids

Reuters reported that Moderna Inc (NASDAQ:MRNA) had made required submissions to the FDA for emergency use authorization of its COVID-19 vaccine in adolescents and children. An advisory panel of experts to the U.S. drug regulator will meet in June to review the request. Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For…

Benzinga

Fourth Covid vaccine provides 'a substantial boost to immunity', according to new study

Several countries have now deployed fourth doses of the Covid-19 vaccine, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain

Daily Mirror

Biden administration and GOP clash over vaccine strategy

The administration wants to keep access as open as possible, but the GOP wants to reduce wastage.

Axios

Read news from The Economist, FT, and more,
with one subscription

COVID-19 Symptoms Rebound After Pfizer's COVID-19 Therapy, What Could Be The Reason?

Some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement after Pfizer Inc's (NYSE: PFE) COVID-19 oral antiviral treatment Paxlovid.

Benzinga

3 ways to get COVID pills, if you've just tested positive

Some people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a COVID test confirms infection.

WEKU

Commentary: The US is doing too little to monitor Paxlovid use

Paxlovid, Pfizer’s antiviral treatment for COVID-19, is turning out to be one of the most successful new drugs in pharma history. Prescriptions have increased tenfold since February, and the five-day pill pack accounts for nearly 90% of the COVID-19 oral-antiviral market.

Tribune News Service

Looking At Pfizer's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

WHO calls on Pfizer to make its COVID pill more available

The head of the World Health Organization has called on Pfizer to make its COVID-19 treatment more widely available in poorer countries

The Independent UK

Covid vaccines are ‘safe for pregnant women and cut stillbirth risk’, study says

Unvaccinated pregnant women who catch Covid-19 are more likely to fall seriously ill

The Independent UK

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion. Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

The Independent UK

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

Daily Record

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

The Guardian - UK

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

The Independent UK

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

The Guardian - UK

Fourth Covid jab can give higher immunity than initial booster, study finds

UK-based team finds antibodies peaked higher after fourth jab given after gap of more than six months than after third

The Independent UK

Fourth booster ‘significantly’ increases protection

Academics have been monitoring the levels of protection post-vaccination.

Bangkok Post

Phuket boy's blindness due to sinusitis, not Pfizer jab

A 12-year-old boy in Phuket did not lose his sight because of Pfizer's coronavirus vaccine but due to severe complications from sinusitis, medical experts on the island province said.

ABC News

High-risk COVID-19 patients can now get two antiviral prescription drugs — but some are still missing out

For Australians at high risk of developing severe COVID-19, getting access to potentially lifesaving treatments recently became easier — but experts say some people are still having trouble obtaining them.

The Independent UK

Rare cases of COVID returning pose questions for Pfizer pill

A small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort

1 … 52 53 54 55

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.